Share

Media invitation: 20th EORTC-NCI-ACR Symposium on Molecular Targets and Cancer Therapeutics

Today is the deadline for booking accommodation via the official local agent

Journalists are invited to attend the 20th EORTC–NCI–AACR Symposium on "Molecular Targets and Cancer Therapeutics" in Geneva, Switzerland [Geneva Palexpo, Geneva] from Tuesday 21 October-Friday 24 October.

Today (Monday 15 September) is the deadline for booking accommodation via the official local agent if you wish to attend this symposium, organised jointly by the European Organisation for the Research and Treatment of Cancer, the US National Cancer Institute and the American Association for Cancer Research.

The symposium offers:

• Cutting edge information on new cancer drug research and development from experts in Europe, North America, Asia and Australia;

• Free registration for bona fide media with official press credentials (press card and/or a commissioning letter from the editor of the journal/website they represent);

• All sessions open to journalists;

• Media centre with free computing, fax, international phone, internet and photocopying facilities;

• Two news briefings (12.15 hrs CEST: Wednesday 22 October and Thursday 23 October)

Topics at the news briefings or to be press released include:

• Crossing the blood-brain barrier: scientists develop a new drug delivery system for hard-to-treat cancers of the central nervous system;

• New "spindle poisoning" drug shows promise in phase I trial of solid tumours: phase II trials planned;

• Scientists discover pattern of gene expression that predicts response to treatment in advanced colorectal cancer;

• New drug shows impressive activity in patients with advanced disease, including medullary thyroid cancer. Phase III trials planned;

• Researchers discover that a genetic mutation makes metastatic colorectal cancer patients resistant to anti-EGFR drugs. Potential for a biomarker to select patients who would respond to treatment;

• Cancer vaccine shows promise in patients with bowel, kidney and prostate cancer: phase III trials on-going.

Please note: the details contained in this media alert are for information only and are embargoed until the time of the news briefings or press releases.

The symposium is an opportunity for journalists to listen and talk to some of the 2,200 European, American and other international experts in oncology gathered in Geneva to share findings on the latest research on new molecular targets, designer diagnostics and prognostics, smart drugs and other novel approaches to cancer treatment.

NB: the official language of the symposium is English and all press materials will be in English.

Journalists should register to attend the symposium by downloading a registration form at: http://www.ecco-org.eu/ or by contacting Riitta Kettunen:
Email: Riitta.Kettunen@ecco-org.eu
Tel: +32 2 775 02 05
Fax: +32 2 775 02 00

More information on the programme and hotel accommodation is available on the EORTC-NCI-AACR symposium website at: http://www.ecco-org.eu/

Accommodation

This should be booked through Symporg SA, the official local agent for the symposium, via the symposium website. Symporg, SA
Tel: +41-22 839 84 84
Fax: +41-22 839 84 85
Email: info@symporg.ch

NB: the deadline for hotel reservations is September 15. Reservations are made on a first-come, first served basis and you are advised to book early.

Share

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.